Analysts Trim IDEXX Price Targets After Q4 EPS and Sales Beat
IDEXX Laboratories reported Q4 earnings of $3.08 per share, up 18% year-over-year, and sales of $1.091 billion, beating consensus estimates of $2.94 and $1.073 billion respectively. Following the release, BTIG lowered its price target to $800 while UBS cut its target to $730, both maintaining their ratings on the stock.
1. Q4 Performance Exceeds Expectations with Broad-Based Growth
IDEXX Laboratories delivered fourth-quarter earnings of $3.08 per share, an 18% year-over-year increase that surpassed the consensus forecast of $2.94. Revenue rose to $1.091 billion, up 14% on a reported basis and 12% organically, topping analyst projections of $1.073 billion. The Companion Animal Group (CAG) led the advance with $998.5 million in sales, driven by a 12% jump in recurring diagnostics revenue and a 76% surge in capital instrument revenues. In this segment, placements of over 1,900 inVue Dx systems and nearly 1,400 Catalyst units fueled instrument revenue gains. Water-testing revenue climbed 12% to $50.5 million, while livestock and poultry diagnostics grew 8% to $37.5 million. Gross profit expanded 15% to $658.1 million, lifting gross margin by 50 basis points to 60.3%, and operating margin rose 150 basis points to 28.9%.
2. Fiscal 2026 Guidance Reflects Continued Momentum and Innovation Pipeline
For fiscal 2026, IDEXX projects earnings of $14.29–$14.80 per share, compared with a consensus estimate of $14.39, and anticipates annual revenue between $4.632 billion and $4.720 billion versus a $4.658 billion consensus. The company expects CAG Diagnostics recurring revenue growth of 8.6%–10.6% as reported (8.0%–10.0% organic), underpinned by an expanding installed base of instruments and software and a robust innovation pipeline. Management highlighted ongoing productivity initiatives in its reference labs, net price realization strategies, and anticipated operating margin expansion, reflecting confidence in offsetting inflationary pressures.
3. Analyst Revisions and Investor Considerations
Following the earnings release, BTIG’s Mark Massaro maintained a Buy rating but reduced his target from $830 to $800, while UBS’s Andrea Alfonso kept a Neutral stance and lowered her target from $750 to $730. Analysts note that guidance slightly below consensus and signs of visit-frequency softness in key end markets pressured sentiment despite strong fundamentals. William Blair emphasized confidence in the new product cycle’s ability to support growth, and Ryan Daniels highlighted the company’s leverage of innovation levers in a challenging environment. Investors will monitor instrument placement trends and software subscription uptake as key drivers of sustained margin expansion and top-line momentum.